{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:47:04Z","timestamp":1787507224839,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Overactive bladder (OAB) is a disease characterized by the presence of urinary urgency. We carried out a meta-analysis to assess the effectiveness and safety of trigonal-involved injection of onabotulinumtoxinA (BoNT-A) in comparison with the trigonal-sparing technique in cases with OAB [neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO)].\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Randomized controlled trials (RCTs) of BoNT-A injection for OAB were searched systematically by using EMBASE, MEDLINE, and the Cochrane Controlled Trials Register. The datum was calculated by RevMan version 5.3.0. The original references of relating articles were also reviewed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In total, six RCTs involving 437 patients were included in our analysis. For OAB, the trigone-including group showed a different patient symptom score (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.03), complete dryness rate (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002), frequency of incontinence episodes (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01), detrusor pressure at maximum flow rate (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01), and volume at the first desire to void (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0004) compared with the trigone-sparing group. Also, a trigone-including intradetrusor injection demonstrated a significant improvement in the patient symptom score (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0004), complete dryness rate (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0002), frequency of incontinence episodes (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0003), detrusor pressure at maximum flow rate (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01), and volume at the first desire to void (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.00006) compared with the trigone-sparing group for treatment of NDO. The adverse events rates were similar in both groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The meta-analysis has demonstrated that trigone-including BoNT-A injection was more effective compared with the trigone-sparing injection for the treatment of OAB, especially for NDO.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2021.651635","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T04:45:21Z","timestamp":1633841121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuanshan","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn."},{"key":"B2","first-page":"S90","article-title":"The total economic burden of overactive bladder in the United States: a disease-specific approach","volume":"15","author":"Onukwugha","year":"2009","journal-title":"Am J Managed Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1517\/14656566.3.7.827","article-title":"Current pharmacotherapeutic strategies for overactive bladder","volume":"3","author":"Garely","year":"2002","journal-title":"Expert Opin Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1600-0404.2010.01376.x","article-title":"Traumatic spinal cord injury and concomitant brain injury: a cohort study","volume":"190","author":"Hagen","year":"2010","journal-title":"Acta neurologica Scandinavica Supplementum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr Opin Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol Urodyn."},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5213\/inj.1732646.323","article-title":"Efficacy and adverse events associated with use of onabotulinumtoxina for treatment of neurogenic detrusor overactivity: a meta-analysis","volume":"21","author":"Yuan","year":"2017","journal-title":"Int Neurourol J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4103\/0366-6999.154318","article-title":"Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"128","author":"Zhou","year":"2015","journal-title":"Chinese Med J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD005493","DOI":"10.1002\/14651858.CD005493.pub3","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","volume":"12","author":"Duthie","year":"2011","journal-title":"Cochrane Datab Syst Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0090-4295(01)01637-5","article-title":"Bladder activation: afferent mechanisms","volume":"59","author":"Andersson","year":"2002","journal-title":"Urology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/bmj.317.7167.1258","article-title":"Randomised controlled trials: a user's guide","volume":"317","author":"Vader","year":"1998","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/luts.12321","article-title":"Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: a randomized clinical trial. Lower urinary tract symptoms","volume":"13","author":"El-Hefnawy","year":"2020","journal-title":"Adv Onl Publ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sc.2015.143","article-title":"Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity","volume":"54","author":"Hui","year":"2016","journal-title":"Spinal Cord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2340\/16501977-2132","article-title":"Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia","volume":"48","author":"Huang","year":"2016","journal-title":"J Rehabil Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol Urodyn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","article-title":"Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity","volume":"61","author":"Manecksha","year":"2012","journal-title":"Eur Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder\u2013to include or exclude the trigone? A prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid","year":"2010","journal-title":"J Urol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/nau.24158","article-title":"Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature","volume":"38","author":"Kasman","year":"2019","journal-title":"Neurourol Urodyn."},{"key":"B27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/JU.0000000000000328","article-title":"Randomized controlled trial of device guided, slow-paced respiration in women with overactive bladder syndrome","volume":"202","author":"Huang","year":"2019","journal-title":"J Urol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol Urodyn."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7192","DOI":"10.1128\/AEM.70.12.7192-7199.2004","article-title":"Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains","volume":"70","author":"Franciosa","year":"2004","journal-title":"Appl Environ Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2011.11.001","article-title":"Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain","volume":"12","author":"Dolly","year":"2012","journal-title":"Curr Opin Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"107","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/nau.23049","article-title":"A three dimensional nerve map of human bladder trigone","volume":"36","author":"Purves","year":"2017","journal-title":"Neurourol Urodyn."},{"key":"B34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.toxicon.2013.01.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions","volume":"67","author":"Chancellor","year":"2013","journal-title":"Toxicon"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0022-5347(05)64571-5","article-title":"Long-term results of Ingelman-Sundberg denervation procedure for urge incontinence refractory to medical therapy","volume":"168","author":"Westney","year":"2002","journal-title":"J Urol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/ca.21186","article-title":"Origins and distribution of nerves to the female urinary bladder: new anatomical findings in the sex differences","volume":"24","author":"Yamaguchi","year":"2011","journal-title":"Clin Anat."},{"key":"B37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/j.pain.0000000000001453","article-title":"Translating peripheral bladder afferent mechanosensitivity to neuronal activation within the lumbosacral spinal cord of mice","volume":"160","author":"Grundy","year":"2019","journal-title":"Pain."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/bju.12266","article-title":"OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium","volume":"112","author":"Collins","year":"2013","journal-title":"BJU Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/nau.20515","article-title":"Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients","volume":"27","author":"Mascarenhas","year":"2008","journal-title":"Neurourol Urodyn."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J Urol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur Urol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00345-017-2121-6","article-title":"The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis","volume":"36","author":"Jo","year":"2018","journal-title":"World J Urol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","article-title":"morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging","volume":"27","author":"Mehnert","year":"2009","journal-title":"World J Urol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.651635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T04:45:23Z","timestamp":1633841123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.651635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":43,"alternative-id":["10.3389\/fneur.2021.651635"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.651635","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"651635"}}